The drug was developed by a leading group of scientists from the Netherlands (Maastricht University), France and Italy, who filed a PCT application with priority date on the 24th of December in 2010. The patent application is fully owned by the research institutes. DualTPharma has obtained a worldwide exclusive license agreement.

Patent Application
Patent application (WO 2012087115) filed in 2010 titled: “Cancer targeting using carbonic anhydrase isoform IX inhibitors”. Publication date: 28/06/2012.

The firm V.O.patents & trademarks provided a second opinion on our IP. The main conclusion is that the present claims were indicated as novel, inventive and that the Freedom to Operate is excellent.